Definitive Contract 75N91021C00026
Award Date
8/1/21
Potential Completion Date
7/31/23
Potential Value
$2M
Federal Agency
National Cancer Institute
Awardee
Senti Biosciences, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $355,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Petri Bio Inc., a small business, under the Small Business Innovation Research (SBIR) Phase I program. The contract is for the development of engineered microbial therapeutics for the treatment of heritable forms of glioma, a type of brain cancer. The work is focused on demonstrating technical feasibility and proof-of-concept for this therapeutic technology....
This firm fixed price contract for $455,000 was awarded by the National Institutes of Health National Cancer Institute to Nvigen Inc. of San Jose, California. The contract is for research under SBIR Phase II topic 403 to develop highly accurate single cell sequencing technologies with spatial resolution capabilities for cancer research applications. The work directly responds to the solicitation seeking proposals in cancer imaging, spatial sequencing, intra-tumor sensing, and other related...
This definitive firm fixed price contract for $246,378 was awarded by the National Institutes of Health National Cancer Institute to Biodepot LLC, a small disadvantaged, woman-owned business. It responds to Topic 407 of the SBIR Phase I solicitation seeking proposals for cloud-based software to support the Cancer Research Data Commons. Placed of performance will be in Seattle, Washington. The SBIR program aims to stimulate technological innovation to meet federal research needs through awards to...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Pieces Technologies Inc., a small business, under the Small Business Innovation Research (SBIR) Phase II program. The contract, worth $1,999,994.00, is for the project titled "Passive and Active AI Screening for Social Determinants of Health and Interventions to Improve Outcomes in the Cancer Patient Population." The contract has a period of performance from September 16,...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
This definitive firm fixed price contract was awarded by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, to Digital Nanogenetics LLC on September 17, 2018. With a potential value of $300,000, the contract is associated with the Small Business Innovation Research Program Phase I and has a completion date of September 19, 2019. The contract has a set aside designation for total small businesses and will support research...
<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>
This is a $455,000 firm fixed price contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS). The contract was awarded to Mrimath LLC, a small disadvantaged, woman-owned limited liability company, for a Small Business Innovation Research (SBIR) Phase I project related to Artificial Intelligence-aided imaging for cancer prevention, diagnosis, and monitoring. The contract has a...